Clinical health publishing
Written by licensed PharmDs, reviewed by practicing physicians. No ads disguised as content. No SEO fluff.
LDL cholesterol is the most commonly cited cardiovascular risk marker — and one of the least accurate. A PharmD explains why ApoB is a superior measure of atherogenic risk, how discordance works, and what your target should be.
A PharmD compares the best direct-to-consumer lab testing companies — Function Health, Ulta Lab Tests, Inside Tracker, Everlywell, and more — on biomarker coverage, accuracy, cost, and clinical usefulness.
The FDA has ended the legal basis for compounded semaglutide and tirzepatide, and major telehealth platforms have already exited the market. A California PharmD explains the regulatory timeline, what it means for patients mid-treatment, and what your real options are right now.
A licensed pharmacist breaks down the real clinical differences between compounded semaglutide and brand-name Ozempic — bioequivalence, safety, the salt form question, and a framework for evaluating your source.
HOMA-IR is the most practical way to detect insulin resistance years before diabetes develops. A PharmD explains the formula, what the numbers mean, how to order the test yourself, and what to do if your score is high.
High-sensitivity CRP is one of the most underused metabolic risk markers in primary care. A PharmD explains what hsCRP measures, how it connects insulin resistance to cardiovascular disease, and what actually moves the number.
Lipoprotein(a) — or Lp(a) — is a genetically inherited cardiovascular risk factor that affects 1 in 5 people and is almost never ordered by primary care. A PharmD breaks down what it is, how to test it, and what to do about it.
Ozempic and Mounjaro dominate headlines, but most coverage misses the clinical substance. A PharmD breaks down semaglutide vs. tirzepatide on mechanism, efficacy, cardiovascular outcomes data, side effects, and who each drug is actually best for.
NMN and NR supplements are everywhere in longevity circles. A PharmD reviews the actual human clinical trial data on NAD+ precursors — what they do, what the evidence shows, and whether they're worth taking.
Peptides like BPC-157, CJC-1295, sermorelin, and TB-500 are everywhere in longevity circles. A PharmD cuts through the noise with honest evidence grades, regulatory context, and a framework for thinking about peptide therapy in 2026.
What actually happens when you stop taking Ozempic or Wegovy — the weight regain data, the physiology behind it, discontinuation symptoms, and what a clinical pharmacist recommends before you stop.
Standard cholesterol panels miss the biomarkers that actually predict cardiovascular risk. A clinical pharmacist explains ApoB, Lp(a), and why a normal LDL-C does not mean your cardiovascular risk is under control.
No articles in this category yet. Check back soon.